How are thiopurines used and monitored by Swedish gastroenterologists when treating patients with inflammatory bowel disease?

References

• Lindqvist M, Hindorf U, Almer S, Peterson C. Thiopurines in inflammatory bowel disease - the role of pharmacogenetics and therapeutic drug monitoring. Curr Pharmacogenet 2006;4:285–300.
   Google Scholar
• Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992;305:20–2.
   PubMed Web of Science ®Google Scholar
• Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132–42.
   PubMed Web of Science ®Google Scholar
• Ford LT, Berg JD. Thiopurine S-methyltransferase (TPMT) assessment prior to starting thiopurine drug treatment; a pharmacogenomic test whose time has come. J Clin Pathol 2010;63:288–95.
   PubMed Web of Science ®Google Scholar
• Reinshagen M, Schutz E, Armstrong VW, Behrens C, Von Tirpitz C, Stallmach A, 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007;53:1306–14.
   PubMed Web of Science ®Google Scholar
• Roblin X, Serre-Debeauvais F, Phelip JM, Faucheron JL, Hardy G, Chartier A, 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine. Aliment Pharmacol Ther 2005;21:829–39.
   PubMed Web of Science ®Google Scholar
• Hindorf U, Lindqvist M, Peterson C, Soderkvist P, Strom M, Hjortswang H, Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 2006;55:1423–31.
   PubMed Web of Science ®Google Scholar
• Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705–13.
   PubMed Web of Science ®Google Scholar
• Almer S, Befrits R, Eriksson AS, Halfvarson J, Hindorf U, Lofberg R. Modern läkemedelsterapi vid Crohn–nationella riktlinjer. [Current drug therapy in Crohn disease–national guidelines]. Läkartidningen 2009;106:2988–93.
   PubMedGoogle Scholar
• Hindorf U, Johansson M, Eriksson A, Kvifors E, Almer SH. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009;29:654–61.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease–a long-term follow-up. Am J Gastroenterol 2006;101:1048–56.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Buschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999;44:625–8.
   PubMed Web of Science ®Google Scholar
• Almer SH, Hjortswang H, Hindorf U. 6-Thioguanine therapy in Crohn's disease–observational data in Swedish patients. Dig Liver Dis 2009;41:194–200.
   PubMedGoogle Scholar
• Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007;5:209–14.
   PubMed Web of Science ®Google Scholar
• Yip JS, Woodward M, Abreu MT, Sparrow MP. How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis 2008;14:514–8.
   PubMedGoogle Scholar
• Roblin X, Oussalah A, Chevaux JB, Sparrow M, Peyrin-Biroulet L. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis 2011. doi:10.1002/ibd.21662. [Epub ahead of print].
   Google Scholar
• Peyrin-Biroulet L, Oussalah A, Roblin X, Sparrow MP. The use of azathioprine in Crohn's disease during pregnancy and in the post-operative setting: a worldwide survey of experts. Aliment Pharmacol Ther 2011;33:707–13.
   PubMed Web of Science ®Google Scholar
• Tysk C, Almer S, Andersson MV, Befrits R, Hertervig E, Kilander A, Handläggning av svårt skov av ulcerös kolit. [Management of severe attack of ulcerative colitis]. Läkartidningen 2009;106:2994–8.
   PubMedGoogle Scholar
• Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362:1383–95.
   PubMed Web of Science ®Google Scholar
• Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut 2006;55:1198–206.
   PubMed Web of Science ®Google Scholar
• Dejaco C, Mittermaier C, Reinisch W, Gasche C, Waldhoer T, Strohmer H, Azathioprine treatment and male fertility in inflammatory bowel disease. Gastroenterology 2001;121:1048–53.
   PubMed Web of Science ®Google Scholar
• Fargher EA, Tricker K, Newman W, Elliott R, Roberts SA, Shaffer JL, Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther 2007;32:187–95.
   PubMed Web of Science ®Google Scholar
• Dewit O, Starkel P, Roblin X. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest 2010;40:1037–47.
   PubMedGoogle Scholar